الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 217 |  |  |
| | | from | 217 | | |
Abstract
The heart is a muscular organ in humans and other animals, which pumps blood through the blood vessels of the circulatory system. Blood provides the body with oxygen and nutrients, as well as assists in the removal of metabolic wastes.
Heart diseases have risen steadily over the last century, especially in industrialized countries, due to changes in diet, lifestyle and abuse of many drugs. Cardiovascular diseases are the most common cause of death globally as of 2008, accounting for 30% of death.
Diabetes mellitus is one of the most common endocrine diseases in the world characterized by the state of hyperglycemia. It is a systemic disease caused by defect in the insulin secretion, insulin action or even both. It is associated with a number of complications leading to retinopathy, nephropathy, peripheral neuropathy, angiopathy, impaired wound healing and gastrointestinal disturbance. Gastrointestinal symptoms include nausea, vomiting, early satiety, abdominal pain, constipation, diarrhea and fecal incontinence which may have negative impact on the patient’s quality of life. Losartan is an angiotensin II type one (AT1) receptor antagonist which has been approved for the management of arterial hypertension. Losartan is also used in diabetics to prevent renal damage, and in patients with heart failure with reduced ejection fraction The aim of this work was to throw some light on effect of Losartan concerning the biochemical, histological, histochemical, ultrastructural and immunohistochemical effects on diabetic heart of adult male rats. Materials & methods: In this study, sixty (60) adult male Sprague-Dawley rats were divided into four groups:
group I (control group): includes 10 animals which received distilled water orally for 8weeks. group II (Losartan treated group): includes 10 animals. which received losartan 30 mg/kg/day for 8 weeks orally. group III (diabetic group): includes 20 animals. received single intraperitoneal injection of STZ solution (12 mg/240 g) for induction of diabetes. group IV (diabetic group treated with losartan): received single intraperitoneal injection of STZ solution (12 mg/240 g) for induction of diabetes and losartan at a dose of 30 mg/kg/day for 8 weeks
In this study, experimental diabetes was induced effectively by a single intraperitoneal injection of STZ solution at a dose of (12 mg/240 g) of body weight. At the end of the experiment all rats were anasesthized, blood samples were collected from rats tail for biochemical study then animals were sacrificed and the heart and aorta were dissected.